IMARA Inc.

NasdaqGS:IMRA Stok Raporu

Piyasa değeri: US$165.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

IMARA Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Rahul Ballal

İcra Kurulu Başkanı

US$2.0m

Toplam tazminat

CEO maaş yüzdesi26.54%
CEO görev süresi4.7yrs
CEO sahipliği0.08%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi4.1yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Oct 13

Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal

Pharmaceutical firms Enliven Therapeutics and Imara (NASDAQ:IMRA) have agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates, IMRA said in a statement on Thursday. Enliven has two cancer drug candidates. The merged entity will be renamed Enliven Therapeutics and is expected to trade on the Nasdaq Global Select Market under the ticker symbol ELVN. To support the merger, Enliven also intends to raise about $165M in a concurrent private financing co-led by new investors Fairmount and Venrock Healthcare Capital Partners. The combined company is expected to have a cash balance of about $300M at close. IMRA stock earlier closed +4.5% at $2.58.
Seeking Alpha • Sep 29

Imara: Potential Liquidation

Summary Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal. The main risk here is management pursuing a reverse-merger. Imara (IMRA) is a failed $60m MCAP biotech company trading at a 37% discount to its Pro Forma net cash levels. In April, the company reduced its workforce by around 83% (to a total of 6 employees), discontinued its treatment development pipeline (relating to both IMR-687 and IMR-261), and commenced a strategic review. A couple of positive developments have occurred since then. In July, the company terminated its headquarter lease agreement to reduce operating expenses. Quite strange that their website still shows their office location; On the 7th of September, IMRA surprised the market by signing a deal to divest its IMR-687 treatment assets to Cardurion Pharmaceuticals. A key condition here is shareholder approval (majority of votes cast need to support the sale), which should easily pass as management holds 40% of shares outstanding. Management has recently released a preliminary proxy related to the sale but the shareholders' meeting date is yet to be announced. Overall it seems that this is a done deal that should close swiftly as there are no major conditions that stand in the way. The company will continue to explore strategic alternatives post-transaction. Discount to Pro-Forma Cash Upon closing of the aforementioned IMR-673 sale, IMRA will receive an upfront cash payment of $34.75m plus two contingent payments. The contingent payments are structured as follows: $10m will be received if the buyer (Cardurion) achieves a proof on concept milestone or other specified clinical milestones; $50m will be received if the buyer (Cardurion) achieves specified regulatory and/or commercial milestone events. Cardurion is a private company, specializing in cardiovascular disease. The company is developing new therapeutics for heart failure and cardiovascular diseases. Looking at their existing portfolio it is highly likely that the IMR-687 purchase will be used for similar purposes. As IMRA reported only plans of clinical development for IMR-687 in heart failures, it seems that even if the milestones get achieved, they would be hit a long way from now. Hence I view the contingent payments as more of a free option here. For context, if both milestones are achieved, shareholders stand to receive another $2.3/share on top of the existing $3.6/share Pro Forma net cash. The table below shows a more conservative scenario where IMRA only received the upfront payments. Discount to Net Cash (Company's Filings) Cash burn was still elevated in Q2 at near $12m but this was due to R&D expenses still being present and some one-off layoff compensations. Excluding the $7.4m in R&D expenses and excluding the one-off compensations, we arrive at an $8m/year cash burn or $0.3/share. According to these assumptions, after 1 year the company would still be trading at a 31% discount from its cash levels. I believe this provides a decent margin of safety for IMRA especially as it continues to explore strategic alternatives. As a bonus, the company also has its IMR-261 asset that can add additional value. However, the upside from such a sale would likely be minimal. Imara purchased this asset in 2020 for an upfront $75k payment plus uncertain contingent payments. This is a very small sum and Imara has done little work with this asset to suggest it is worth more than it did two years ago. IMR-261 is barely in phase 1 vs phase 2 for the sold IMR-687 treatment. As a side note, management did not comment on whether these sale proceeds will be taxable or not. IMRA has around $270m worth of NOL’s which can most likely be used to offset taxes. So the upfront cash payment of $34.75m is treated as net proceeds. Possible Scenarios Though the outcome of the strategic review is still uncertain, the ideal scenario would be a full-on liquidation of the company. Post-asset sale Imara is basically a cash shell with no operations and no headquarters. Management owns 40% so it would also benefit from a liquidation. The main risk here is that management pursues a reverse merger. Though management owns 40%, they are also used to receiving high salaries. A similar situation has recently happened with IMRA’s peer Sesen Bio. On the 21st of September SESN announced a reverse merger sending SESN’s shares down by 40%. Note that SESN was also a failed biopharma that traded below net-cash levels and announced a strategic review.
Analiz Makalesi • Jul 23

We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Sep 09

We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analiz Makalesi • May 03

Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analiz Makalesi • Jan 11

Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Tazminat Analizi

Rahul Ballal'un ücretlendirmesi IMARA'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2022n/an/a

US$1m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$56m

Dec 31 2021US$2mUS$518k

-US$51m

Sep 30 2021n/an/a

-US$49m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$626kUS$437k

-US$49m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$34m

Dec 31 2019US$2mUS$422k

-US$23m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$938kUS$242k

-US$11m

Tazminat ve Piyasa: Rahul 'ın toplam tazminatı ($USD 1.95M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.73M ).

Tazminat ve Kazançlar: Rahul 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rahul Ballal (44 yo)

4.7yrs
Görev süresi
US$1,951,029
Tazminat

Dr. Rahul D. Ballal, Ph D., is the Chief Executive Officer of Imara Inc. June 13, 2018. Dr. Rahul serves as Director of Agios Pharmaceuticals, Inc. since August 2022.Dr. Ballal is President and Director a...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Rahul Ballal
President4.7yrsUS$1.95m0.084%
$ 140.0k
Michael Gray
CFO & COO3.8yrsUS$1.22m0.030%
$ 50.3k
Stephen Migausky
Senior VP of Legal & General Counsel2.8yrsVeri yokVeri yok
3.8yrs
Ortalama Görev Süresi

Deneyimli Yönetim: IMRA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Rahul Ballal
President4.7yrsUS$1.95m0.084%
$ 140.0k
Barbara Dalton
Independent Director7.1yrsUS$82.17k0%
$ 0
David Mott
Independent Chairman7.1yrsUS$120.59k0.87%
$ 1.4m
Carl Goldfischer
Independent Director7.1yrsUS$90.65k0%
$ 0
Joel Marcus
Board Observerno dataVeri yokVeri yok
David Bonita
Independent Director3.9yrsUS$80.65k0%
$ 0
Mark Chin
Independent Director3.9yrsUS$85.68k0%
$ 0
Kim Andersen
Board Observer4.1yrsVeri yokVeri yok
Laura Williams
Independent Director1.7yrsUS$105.62k0%
$ 0
Edward Conner
Independent Director2.8yrsUS$79.65k0%
$ 0
Matthew Hammond
Board Observer4.1yrsVeri yokVeri yok
John Cassidy
Board Observer4.1yrsVeri yokVeri yok
4.1yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: IMRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/02/24 00:44
Gün Sonu Hisse Fiyatı2023/02/23 00:00
Kazançlar2022/12/31
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

IMARA Inc. 4 Bu analistlerden , raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Yigal NochomovitzCitigroup Inc
Edward WhiteH.C. Wainwright & Co.
Joseph SchwartzLeerink Partners LLC